Request Your Free Trend Report Now:

"The state of biosimilars in 2024"

As commercial momentum builds, coverage incentives for the Medicare market are expected to favor biosimilars in 2025. Explore where the market is headed in the U.S. in this Trendline.

Although the U.S. biosimilars market has fallen short of expectations since its first product approval in 2015, more have poured onto the market after a slow start. Greater price competition could emerge as more biosimilars of each drug begin to launch.

included in this trendline

• Cigna CEO promises ‘aggressive’ defense of pharmacy benefit managers
• PBMs battle bipartisan scrutiny as lawmakers eye reforms
• Boehringer cuts price of Humira biosimilar in bid to build use

Offered Free by: PharmaVoice and PurpleLab
See All Resources from: PharmaVoice and PurpleLab